☆ 4.8 Review

Neoadjuvant immunotherapy for resectable esophageal cancer: A review

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study

Jun Liu et al.

Summary: This study assessed the use of neoadjuvant camrelizumab plus chemotherapy in patients with resectable esophageal squamous cell carcinoma. The results showed that this treatment approach had promising efficacy and acceptable toxicity, providing an effective option for patients.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Y. Doki et al.

Summary: In patients with advanced esophageal squamous-cell carcinoma, both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone, with no new safety signals identified.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Wenwu He et al.

Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

Weixiong Yang et al.

Summary: This study evaluated the safety and feasibility of using PD-1 blockade in combination with chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The results showed that this neoadjuvant treatment regimen had manageable side effects and induced an objective response in 90.5% of patients, demonstrating its antitumor efficacy in resectable ESCC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zi-Xian Wang et al.

Summary: This study found that toripalimab combined with paclitaxel and cisplatin can significantly improve progression-free survival and overall survival in patients with treatment-naive advanced esophageal squamous cell carcinoma, with manageable safety.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Mojun Zhu et al.

Summary: This study investigated the feasibility and efficacy of pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction adenocarcinoma. The results showed that adding pembrolizumab was tolerable but did not meet the expected pathologic complete response rate. Patients with high PD-L1 expression were more likely to achieve tumor response.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer

Sarah M. H. Einerhand et al.

Summary: This study compared the clinical outcomes of neoadjuvant/induction platinum-based combination chemotherapy (NAIC) with combination immune checkpoint inhibition (cICI) in patients with locally advanced urothelial carcinoma. The results showed that cICI was associated with superior progression-free survival and overall survival compared to NAIC. This provides a strong rationale for validating cICI as the standard treatment for locally advanced urothelial carcinoma.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Lin Shen et al.

Summary: Tislelizumab significantly improves overall survival in patients with advanced or metastatic ESCC, and has a tolerable safety profile. Patients with TAP >= 10% also demonstrate significant survival benefit with tislelizumab compared to chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Surgery

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)

Xiaolong Yan et al.

Summary: This study evaluated the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The results showed that this treatment approach had high rates of major pathological response and pathological complete response, and the tolerability was acceptable.

INTERNATIONAL JOURNAL OF SURGERY (2022)

添加到收藏夹

Article Medicine, General & Internal

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lu et al.

Summary: This study evaluated the efficacy of sintilimab in combination with chemotherapy for patients with unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. The results demonstrated significant improvements in overall survival and progression free survival with sintilimab plus cisplatin and paclitaxel compared to placebo plus chemotherapy. Similar benefits were seen with sintilimab plus cisplatin and 5-fluorouracil.

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Article Immunology

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

Hongtao Duan et al.

Summary: This single-arm study evaluated the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The study found that the combination treatment resulted in a high pathological response and immunologic effects in the tumor microenvironment. These findings suggest that further evaluation in randomized clinical trials is warranted.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Jun Liu et al.

Summary: The study demonstrated the safety and efficacy of camrelizumab plus neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma, achieving a high rate of pathologically complete response and manageable adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)

Lei Gao et al.

Summary: This study confirms the safety and efficacy of toripalimab combined with docetaxel and cisplatin as a neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

S. Loibl et al.

Summary: Adding durvalumab to neoadjuvant chemotherapy in patients with TNBC significantly improved survival rates, despite a modest increase in pCR, and without a durvalumab adjuvant component.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Surgery

Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis

Zhaoyang Wang et al.

Summary: The present study conducted a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy in patients with locally advanced esophageal cancer (EC). The results showed that neoadjuvant immunotherapy, especially when combined with chemotherapy or chemoradiotherapy, was safe and effective. Moreover, it was found that neoadjuvant immunotherapy could improve safety while achieving comparable efficacy compared to traditional neoadjuvant therapeutic regimens. However, further studies are needed to investigate the long-term outcomes of neoadjuvant immunotherapy in EC.

INTERNATIONAL JOURNAL OF SURGERY (2022)

添加到收藏夹

Article Oncology

Effects of Radiotherapy on Survival of Esophageal Cancer Patients Receiving Immunotherapy Propensity Score Analysis and Nomogram Construction

Yuanliu Nie et al.

Summary: This study assessed the effects of immunotherapy plus radiotherapy on survival outcomes in patients with advanced esophageal cancer and established a prognostic nomogram based on independent prognostic factors. The results showed that immunotherapy plus radiotherapy resulted in significantly longer progression-free survival and overall survival compared to immunotherapy alone. The nomogram based on prognostic factors can guide personalized treatment and monitoring of prognosis.

CANCER MANAGEMENT AND RESEARCH (2022)

添加到收藏夹

Review Medicine, General & Internal

Enhancing anti-tumour efficacy with immunotherapy combinations

Funda Meric-Bernstam et al.

Summary: This article evaluates immune therapy response biomarkers to identify patients who benefit from monotherapy rather than combination therapy. It also reviews the rationale and strategies for combination therapy, including combinations with chemotherapy, targeted therapy, and other immunomodulators.

LANCET (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Tom van den Ende et al.

Summary: The study demonstrated the feasibility of combining nCRT with PD-L1 inhibition for patients with rEAC. Most patients proceeded to surgery after receiving all cycles of atezolizumab, and some experienced immune-related adverse events. Exploratory biomarker analysis suggested the potential of neoadjuvant immunotherapy in certain patient subgroups.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

Chengqiang Li et al.

Summary: This study investigated the safety and efficacy of preoperative pembrolizumab combined with chemoradiotherapy in resectable oesophageal squamous cell carcinoma patients. The results showed that this treatment was safe and induced a pathological complete response in 55.6% of the tumors.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Review Oncology

Paradigms on Immunotherapy Combinations with Chemotherapy

Diego Salas-Benito et al.

Summary: Checkpoint inhibitors are being added to standard-of-care chemotherapy in clinical trials with success reported in various cancer types, but chemotherapy regimens have not been optimized for these combinations; optimal approaches to chemo-immunotherapy should include neoadjuvant and adjuvant schemes to maximize the benefits of both treatments.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Peng Yang et al.

Summary: Neoadjuvant camrelizumab plus chemotherapy demonstrates good efficacy and acceptable tolerance in patients with locally advanced ESCC, with promising clinical prospects.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma

Dijian Shen et al.

Summary: The study evaluated the efficacy and safety of PD-1 inhibitor in neoadjuvant chemotherapy for locally advanced ESCC, showing a high pCR rate and R0 resection rate with low toxicity. Long-term efficacy of this novel treatment should be confirmed with longer follow-up and prospective trials.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Immunology

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study

Wenqun Xing et al.

Summary: There is no standard neoadjuvant therapy for locally advanced esophageal cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer is still being explored. Results from this study suggest that delaying the administration of toripalimab to day 3 in chemoimmunotherapy may achieve a higher pCR rate, indicating the need for further large-sample clinical trials to confirm these findings.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)

Hongtao Duan et al.

Summary: This study evaluated the efficacy and safety of neoadjuvant therapy with sintilimab in combination with chemotherapy for esophageal cancer. The results showed that this treatment was safe and led to a high pathological complete response rate, suggesting further testing is warranted.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)

Zhenyang Zhang et al.

Summary: This study investigated the safety and feasibility of combining neoadjuvant sintilimab and chemotherapy for locally advanced esophageal squamous cell carcinoma. Results showed that this combination therapy was well-tolerated with promising efficacy, high R0 resection rate, and manageable postoperative complications. Further multicenter, randomized trials are needed to confirm these findings.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma

Annette M. Lim et al.

Summary: This article discusses the high incidence of non-melanoma skin cancers in Australia and New Zealand, as well as the revolutionary impact of immune checkpoint inhibition on the treatment of locally advanced and metastatic cutaneous squamous cell carcinomas. It highlights treatment issues unique to the management of the disease, such as delayed responses and the development of second primary tumors, while also exploring the heterogeneous disease responses and expanding clinical boundaries for immunotherapy use.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

W. Yao et al.

Summary: The study explored the impact of combining anti-PD-1 antibody with chemotherapy on cytotoxic effects in peripheral blood mononuclear cells. Results showed that administering the anti-PD-1 Ab 3 days after chemotherapy weakened cytotoxic effects on lymphocytes compared to administration before or concurrent with chemotherapy. Retrospective analysis in refractory lung cancer patients indicated that administering PD-1/PD-L1 inhibitors 1-10 days after chemotherapy, especially 3-5 days after, was associated with longer overall survival.

ESMO OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

Huiyan Luo et al.

Summary: The addition of camrelizumab to chemotherapy significantly improved overall survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma. This treatment strategy could enhance the overall survival rate of patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Review Multidisciplinary Sciences

Neoadjuvant checkpoint blockade for cancer immunotherapy

Suzanne L. Topalian et al.

SCIENCE (2020)

添加到收藏夹

Review Oncology

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

Jose Carlos Benitez et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Oncology

Clinical Challenges of Immune Checkpoint Inhibitors

Maria de Miguel et al.

CANCER CELL (2020)

添加到收藏夹

Review Oncology

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Lorenzo Galluzzi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Treatment after progression in the era of immunotherapy

Salem Billan et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Surgery

PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer

Taisuke Yagi et al.

ANNALS OF SURGERY (2019)

添加到收藏夹

Meeting Abstract Oncology

Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer.

Ronan Joseph Kelly et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Kurt A. Schalper et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Oncology

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

Jing Lio et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

Laura M. McLane et al.

Annual Review of Immunology (2019)

添加到收藏夹

Review Oncology

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment

Jake S. O'Donnell et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

Nataliya Volodymyrivna Uboha et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).

Min Hee Hong et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis

Yucai Wang et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma

Eiji Fukuoka et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence

Max Lacour et al.

CLINICAL LUNG CANCER (2019)

添加到收藏夹

Review Oncology

Esophageal and Esophagogastric Junction Cancers, Version 2.2019

Jaffer A. Ajani et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

添加到收藏夹

Article Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Peng Liu et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Oncology

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy

Eric Deutsch et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer

So-Jin Park et al.

ORAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy

Xiu-Yong Liao et al.

ONCOLOGY LETTERS (2019)

添加到收藏夹

Article Oncology

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Ludovic Fournel et al.

CANCER LETTERS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles et al.

NATURE MEDICINE (2019)

添加到收藏夹

Editorial Material Cell Biology

Intratumoral CD8+T cells with stem cell-like properties: Implications for cancer immunotherapy

Werner Held et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Review Oncology

Novel patterns of response under immunotherapy

E. Borcoman et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

K. M. Heinhuis et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy

Wan-Ting Huang et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Genetics & Heredity

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert M. Samstein et al.

NATURE GENETICS (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

Caroline S. Jansen et al.

NATURE (2019)

添加到收藏夹

Article Immunology

Defining 'T cell exhaustion'

Christian U. Blank et al.

NATURE REVIEWS IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

T. R. Cottrell et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Epidemiology of Esophageal Squamous Cell Carcinoma

Christian C. Abnet et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Review Immunology

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

Shetal A. Patel et al.

IMMUNITY (2018)

添加到收藏夹

Review Oncology

Safety of combining radiotherapy with immune-checkpoint inhibition

William L. Hwang et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Review Oncology

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

Jun Gong et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Meeting Abstract Oncology

Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse

Stephen Mok et al.

CANCER RESEARCH (2018)

添加到收藏夹

Meeting Abstract Oncology

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study-NADIM study-SLCG.

Mariano Provencio-Pulla et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

Hong Yang et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman et al.

CELL (2018)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018)

Rodabe N. Amaria et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Is earlier better for melanoma checkpoint blockade?

Caroline Robert

NATURE MEDICINE (2018)

添加到收藏夹

Review Oncology

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Yixin Zhou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

Charlotte Leduc et al.

ESMO OPEN (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Integrated genomic characterization of oesophageal carcinoma

Jihun Kim et al.

NATURE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

cGAS surveillance of micronuclei links genome instability to innate immunity

Karen J. Mackenzie et al.

NATURE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Mitotic progression following DNA damage enables pattern recognition within micronuclei

Shane M. Harding et al.

NATURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Letter Medicine, General & Internal

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

Mark Yarchoan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor

Wencheng Zhang et al.

CANCER SCIENCE (2017)

添加到收藏夹

Article Immunology

Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model

Yanhong Wu et al.

BMC IMMUNOLOGY (2016)

添加到收藏夹

Review Oncology

Systematic review of case reports on the abscopal effect

Yazan Abuodeh et al.

CURRENT PROBLEMS IN CANCER (2016)

添加到收藏夹

Article Oncology

The immune mechanisms of abscopal effect in radiation therapy

G. Daniel Grass et al.

CURRENT PROBLEMS IN CANCER (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population

Genta Sawada et al.

GASTROENTEROLOGY (2016)

添加到收藏夹

Article Immunology

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Christina Pfirschke et al.

IMMUNITY (2016)

添加到收藏夹

Article Oncology

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Jing Liu et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression

Miao-Fen Chen et al.

ONCOTARGET (2016)

添加到收藏夹

Article Respiratory System

Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis

Hai-Xia Qu et al.

JOURNAL OF THORACIC DISEASE (2016)

添加到收藏夹

Review Oncology

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Suzanne L. Topalian et al.

NATURE REVIEWS CANCER (2016)

添加到收藏夹

Article Genetics & Heredity

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma

Ling Zhang et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2015)

添加到收藏夹

Review Oncology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Lorenzo Galluzzi et al.

CANCER CELL (2015)

添加到收藏夹

Review Oncology

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

Kobe Reynders et al.

CANCER TREATMENT REVIEWS (2015)

添加到收藏夹

Review Oncology

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

Andrew B. Sharabi et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joel Shapiro et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor et al.

NATURE (2015)

添加到收藏夹

Review Oncology

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Jonathan Pol et al.

ONCOIMMUNOLOGY (2015)

添加到收藏夹

Article Immunology

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Liufu Deng et al.

IMMUNITY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Article Medicine, General & Internal

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar et al.

LANCET (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Identification of genomic alterations in oesophageal squamous cell cancer

Yongmei Song et al.

NATURE (2014)

添加到收藏夹

Article Genetics & Heredity

Genetic landscape of esophageal squamous cell carcinoma

Yi-Bo Gao et al.

NATURE GENETICS (2014)

添加到收藏夹

Article Genetics & Heredity

Genomic and molecular characterization of esophageal squamous cell carcinoma

De-Chen Lin et al.

NATURE GENETICS (2014)

添加到收藏夹

Article Oncology

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

Elena Garcia-Martinez et al.

BREAST CANCER RESEARCH (2014)

添加到收藏夹

Article Nutrition & Dietetics

Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells

Hiromi Sakai et al.

JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov et al.

NATURE (2013)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer Genome Landscapes

Bert Vogelstein et al.

SCIENCE (2013)

添加到收藏夹

Review Oncology

Esophageal carcinoma advances in treatment results for locally advanced disease: review

A. Herskovic et al.

ANNALS OF ONCOLOGY (2012)

添加到收藏夹

Article Immunology

Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

Anurag Gupta et al.

JOURNAL OF IMMUNOLOGY (2012)

添加到收藏夹

Article Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Apar Pataer et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Review Biology

Cytokines in Radiobiological Responses: A Review

Doerthe Schaue et al.

RADIATION RESEARCH (2012)

添加到收藏夹

Review Oncology

Role of T lymphocytes in tumor response to radiotherapy

Sandra Demaria et al.

FRONTIERS IN ONCOLOGY (2012)

添加到收藏夹

Review Oncology

Immunogenic cell death and DAMPs in cancer therapy

Dmitri V. Krysko et al.

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Oncology

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy

W. Fraser Symmans et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Immunology

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

AA Lugade et al.

JOURNAL OF IMMUNOLOGY (2005)

添加到收藏夹

Article Oncology

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

Y Ohigashi et al.

CLINICAL CANCER RESEARCH (2005)

添加到收藏夹

Article Oncology

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

S Demaria et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.